Daniela Matei

24PUBLICATIONS
60CO-AUTHORS
Gene and molecular therapyMolecular targetsDiscourse and pragmaticsCancer cell biologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|May 04, 2026
Effects of the Hypomethylating Agent Guadecitabine on Peripheral Blood Mononuclear Cell Methylomes and Immune Cell Populations in Small-Cell Lung Cancer Patients.

|Apr 08, 2026
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

Yvette Drew, Lucy Gilbert, Alejandro Martinez Bueno

|Feb 12, 2026
Epitranscriptomic Regulation of Platinum Resistance via the METTL3-ADAM23 Axis in Ovarian Cancer.

Ujin Kim, Junzui Li, Daniela Matei

|Oct 15, 2025
Metabolic Dependency on De Novo Pyrimidine Synthesis Is a Targetable Vulnerability in Platinum-Resistant Ovarian Cancer.

Horacio Cardenas, Yinu Wang, Guangyuan Zhao

|May 30, 2025
CRISPR screen reveals a simultaneous targeted mechanism to reduce cancer cell selenium and increase lipid oxidation to induce ferroptosis.

Sophia M Lamperis, Kaylin M McMahon, Andrea E Calvert

|Apr 10, 2025
Reply to: Comment on The Study of NRG258: Limitations and Future Directions.

Daniela Matei

Pageof 4

Frequent Collaborators

6 joint publications

Yinu Wang

5 joint publications

Guangyuan Zhao

3 joint publications

Horacio Cardenas

3 joint publications

Hao Huang